{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:15:25Z","timestamp":1761894925605},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T00:00:00Z","timestamp":1246320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s11899-009-0024-3","type":"journal-article","created":{"date-parts":[[2009,6,29]],"date-time":"2009-06-29T04:32:45Z","timestamp":1246249965000},"page":"175-182","source":"Crossref","is-referenced-by-count":8,"title":["Update on developmental therapeutics for acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"4","author":[{"given":"Malcolm A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,30]]},"reference":[{"key":"24_CR1","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2003-08-2911","volume":"103","author":"N.L. Liem","year":"2004","unstructured":"Liem NL, Papa RA, Milross CG, et al.: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004, 103:3905\u20133914.","journal-title":"Blood"},{"key":"24_CR2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"D.T. Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Cooperman J, et al.: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006, 107:1149\u20131155.","journal-title":"Blood"},{"key":"24_CR3","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-07-5090","volume":"14","author":"G. Neale","year":"2008","unstructured":"Neale G, Su X, Morton CL, et al.: Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572\u20134583.","journal-title":"Clin Cancer Res"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"C.G. Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, et al.: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758\u2013764.","journal-title":"Nature"},{"key":"24_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"C.G. Mullighan","year":"2009","unstructured":"Mullighan CG, Su X, Zhang J, et al.: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470\u2013480.","journal-title":"N Engl J Med"},{"key":"24_CR6","doi-asserted-by":"crossref","unstructured":"Schultz KR, Bowman WP, Slayton W, et al.: Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children\u2019s Oncology Group (COG) Study AALL0031 [abstract 4]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 4.","DOI":"10.1182\/blood.V110.11.4.4"},{"key":"24_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-008-0223-z","volume":"89","author":"M. Yanada","year":"2009","unstructured":"Yanada M, Ohno R, Naoe T: Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2009, 89:3\u201313.","journal-title":"Int J Hematol"},{"key":"24_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","volume":"14","author":"P.J. Carter","year":"2008","unstructured":"Carter PJ, Senter PD: Antibody-drug conjugates for cancer therapy. Cancer J 2008, 14:154\u2013169.","journal-title":"Cancer J"},{"key":"24_CR9","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"G.D. Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280\u20139290.","journal-title":"Cancer Res"},{"key":"24_CR10","doi-asserted-by":"crossref","unstructured":"Burris HA, Vukelja S, Rugo HS, et al.: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC) [abstract 155]. ASCO 2008 Breast Cancer Symposium 2008, Abstract 155.","DOI":"10.1158\/0008-5472.SABCS-33"},{"key":"24_CR11","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"J.A. Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, et al.: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:1458\u20131465.","journal-title":"Blood"},{"key":"24_CR12","doi-asserted-by":"crossref","unstructured":"Younes A, Forero-Torres A, Bartlett NL, et al.: Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas [abstract 1006]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1006.","DOI":"10.1200\/jco.2008.26.15_suppl.8526"},{"key":"24_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1389201013378635","volume":"2","author":"R.J. Kreitman","year":"2001","unstructured":"Kreitman RJ: Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2001, 2:313\u2013325.","journal-title":"Curr Pharm Biotechnol"},{"key":"24_CR14","doi-asserted-by":"crossref","unstructured":"Aboukameel A, Goustin AS, Mohammad R, et al.: Superior anti-tumor activity of the CD19-directed immunotoxin, SAR3419 to rituximab in non-Hodgkins xenograft animal models: preclinical evaluation [abstract 2339]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 2339.","DOI":"10.1182\/blood.V110.11.2339.2339"},{"key":"24_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6349(08)72124-4","volume":"6","author":"R. Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton P, et al.: Pediatric preclinical testing program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419 [abstract 192]. Eur J Cancer Suppl 2008, 6:61.","journal-title":"Eur J Cancer Suppl"},{"key":"24_CR16","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/blood-2008-09-179143","volume":"113","author":"H.P. Gerber","year":"2009","unstructured":"Gerber HP, Kung-Sutherland M, Stone I, et al.: Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009, 113:4352\u20134361.","journal-title":"Blood"},{"key":"24_CR17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"J.F. DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, et al.: Antibodytargeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004, 103:1807\u20131814.","journal-title":"Blood"},{"key":"24_CR18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"J.F. DiJoseph","year":"2007","unstructured":"DiJoseph JF, Dougher MM, Armellino DC, et al.: Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007, 21:2240\u20132245.","journal-title":"Leukemia"},{"key":"24_CR19","doi-asserted-by":"crossref","unstructured":"Fayad L, Patel HK, Verhoef G, et al.: Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study [abstract 2711]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2711.","DOI":"10.1182\/blood.V108.11.2711.2711"},{"key":"24_CR20","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","volume":"23","author":"R.J. Kreitman","year":"2005","unstructured":"Kreitman RJ, Squires DR, Stetler-Stevenson M, et al.: Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005, 23:6719\u20136729.","journal-title":"J Clin Oncol"},{"key":"24_CR21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","volume":"15","author":"R.F. Alderson","year":"2009","unstructured":"Alderson RF, Kreitman RJ, Chen T, et al.: CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009, 15:832\u2013839.","journal-title":"Clin Cancer Res"},{"key":"24_CR22","doi-asserted-by":"crossref","unstructured":"Wayne A, Findley HW, Lew G, et al.: Pre-clinical studies and phase I clinical trial of the anti-CD22 immunotoxin CAT-3888 (BL22) for pediatric acute lymphoblastic leukemia (ALL) [abstract 9560]. J Clin Oncol 2007, 25 (18 Suppl): Abstract 9560.","DOI":"10.1200\/jco.2007.25.18_suppl.9560"},{"key":"24_CR23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P. Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, et al.: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer 2005, 115:98\u2013104.","journal-title":"Int J Cancer"},{"key":"24_CR24","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","volume":"170","author":"T. Dreier","year":"2003","unstructured":"Dreier T, Baeuerle PA, Fichtner I, et al.: T cell costimulusindependent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3-bispecific single-chain antibody construct. J Immunol 2003, 170:4397\u20134402.","journal-title":"J Immunol"},{"key":"24_CR25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-005-0001-1","volume":"55","author":"B. Schlereth","year":"2006","unstructured":"Schlereth B, Quadt C, Dreier T, et al.: T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006, 55:503\u2013514.","journal-title":"Cancer Immunol Immunother"},{"key":"24_CR26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R. Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, et al.: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974\u2013977.","journal-title":"Science"},{"key":"24_CR27","doi-asserted-by":"crossref","unstructured":"Topp M, Goekbuget N, Kufer P, et al.: Treatment with anti-CD 19 BiTE antibody blinatumomab (MT103 \/MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): first results of an ongoing phase II study [abstract 1926]. Blood (ASH Annual Meeting Abstracts) 2008, 112: Abstract 1926.","DOI":"10.1182\/blood.V112.11.1926.1926"},{"key":"24_CR28","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/sj.onc.1210370","volume":"26","author":"J.P. Leonard","year":"2007","unstructured":"Leonard JP, Goldenberg DM: Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007, 26:3704\u20133713.","journal-title":"Oncogene"},{"key":"24_CR29","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","volume":"26","author":"E.A. Raetz","year":"2008","unstructured":"Raetz EA, Cairo MS, Borowitz MJ, et al.: Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study. J Clin Oncol 2008, 26:3756\u20133762.","journal-title":"J Clin Oncol"},{"key":"24_CR30","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"M.N. Dworzak","year":"2008","unstructured":"Dworzak MN, Schumich A, Printz D, et al.: CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008, 112:3982\u20133988.","journal-title":"Blood"},{"key":"24_CR31","doi-asserted-by":"crossref","unstructured":"Thomas DA, Kantarjian H, Faderl S, et al.: Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) [abstract 1931]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1931.","DOI":"10.1182\/blood.V112.11.1931.1931"},{"key":"24_CR32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","volume":"14","author":"C. Viseur le","year":"2008","unstructured":"le Viseur C, Hotfilder M, Bomken S, et al.: In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14:47\u201358.","journal-title":"Cancer Cell"},{"key":"24_CR33","doi-asserted-by":"crossref","unstructured":"Infante J, Dees EC, Cohen RB, et al.: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States [abstract 280]. Eur J Cancer Suppl 2008, 6:Abstract 280.","DOI":"10.1016\/S1359-6349(08)72214-6"},{"key":"24_CR34","unstructured":"Houghton PJ, Morton CL, Maris JM, et al.: Pediatric preclinical testing program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237 [abstract 2997]. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA; April 12\u201316, 2008."},{"key":"24_CR35","first-page":"93","volume":"6","author":"M.A. Smith","year":"2008","unstructured":"Smith MA, Houghton PJ, Morton CL, et al.: Pediatric preclinical testing program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237 [abstract 286]. Eur J Cancer Suppl 2008, 6:93.","journal-title":"Eur J Cancer Suppl"},{"key":"24_CR36","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","volume":"111","author":"V. Gaizo Moore Del","year":"2008","unstructured":"Del Gaizo Moore V, Schlis KD, Sallan SE, et al.: BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008, 111:2300\u20132309.","journal-title":"Blood"},{"key":"24_CR37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","volume":"141","author":"B.W. Robinson","year":"2008","unstructured":"Robinson BW, Behling KC, Gupta M, et al.: Abundant antiapoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol 2008, 141:827\u2013839.","journal-title":"Br J Haematol"},{"key":"24_CR38","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C. Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, et al.: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421\u20133428.","journal-title":"Cancer Res"},{"key":"24_CR39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","volume":"50","author":"R. Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton PJ, et al.: Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1181\u20131189.","journal-title":"Pediatr Blood Cancer"},{"key":"24_CR40","doi-asserted-by":"crossref","unstructured":"Wilson WH, Czuczman MS, LaCasce AS, et al.: A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies [abstract 8511]. J Clin Oncol 2008, 26(May 20 suppl):Abstract 8511.","DOI":"10.1200\/jco.2008.26.15_suppl.8511"},{"key":"24_CR41","doi-asserted-by":"crossref","unstructured":"Roberts A, Gandhi L, O\u2019Connor OA, et al.: Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263 [abstract 3542]. J Clin Oncol 2008, 26(May 20 suppl):Abstract 3542.","DOI":"10.1200\/jco.2008.26.15_suppl.3542"},{"key":"24_CR42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402072","volume":"14","author":"H. Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, et al.: Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943\u2013951.","journal-title":"Cell Death Differ"},{"key":"24_CR43","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","volume":"110","author":"M.H. Kang","year":"2007","unstructured":"Kang MH, Kang YH, Szymanska B, et al.: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057\u20132066.","journal-title":"Blood"},{"key":"24_CR44","doi-asserted-by":"crossref","unstructured":"Shore G, Watson M, Roulston A, et al.: Obatoclax (GX15-070) is a potent antagonist of constitutive Mcl-1\/Bak interactions in intact mitochondrial membrane and synergizes with bortezomib in mantle cell lymphoma [abstract 832]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 832.","DOI":"10.1182\/blood.V108.11.832.832"},{"key":"24_CR45","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","volume":"14","author":"A.D. Schimmer","year":"2008","unstructured":"Schimmer AD, O\u2019Brien S, Kantarjian H, et al.: A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:8295\u20138301.","journal-title":"Clin Cancer Res"},{"key":"24_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","volume":"113","author":"S.M. O\u2019Brien","year":"2009","unstructured":"O\u2019Brien SM, Claxton DF, Crump M, et al.: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299\u2013305.","journal-title":"Blood"},{"key":"24_CR47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428190701411458","volume":"48","author":"K.A. Blum","year":"2007","unstructured":"Blum KA, Johnson JL, Niedzwiecki D, et al.: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313\u20131319.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"24_CR48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.leu.2401705","volume":"14","author":"U. Kordes","year":"2000","unstructured":"Kordes U, Krappmann D, Heissmeyer V, et al.: Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000:14(3):399\u2013402.","journal-title":"Leukemia"},{"key":"24_CR49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nm1524","volume":"13","author":"T. Vilimas","year":"2007","unstructured":"Vilimas T, Mascarenhas J, Palomero T, et al.: Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007, 13:70\u201377.","journal-title":"Nat Med"},{"key":"24_CR50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","volume":"50","author":"P.J. Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:37\u201345.","journal-title":"Pediatr Blood Cancer"},{"key":"24_CR51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","volume":"58","author":"T.M. Horton","year":"2006","unstructured":"Horton TM, Gannavarapu A, Blaney SM, et al.: Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006, 58:13\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"24_CR52","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","volume":"13","author":"T.M. Horton","year":"2007","unstructured":"Horton TM, Pati D, Plon SE, et al.: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children\u2019s Oncology Group study. Clin Cancer Res 2007, 13:1516\u20131522.","journal-title":"Clin Cancer Res"},{"key":"24_CR53","doi-asserted-by":"crossref","unstructured":"Messinger YH, Gaynon PS, Raetz E, et al.: Remarkable activity of bortezomib combined with chemotherapy in a phase I study of relapsed childhood acute lymphoblastic leukemia (ALL). A report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium [abstract 1919]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1919.","DOI":"10.1182\/blood.V112.11.1919.1919"},{"key":"24_CR54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pbc.21296","volume":"50","author":"P.J. Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:799\u2013805.","journal-title":"Pediatr Blood Cancer"},{"key":"24_CR55","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","volume":"112","author":"D.T. Teachey","year":"2008","unstructured":"Teachey DT, Sheen C, Hall J, et al.: mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008, 112:2020\u20132023.","journal-title":"Blood"},{"key":"24_CR56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"G. Wei","year":"2006","unstructured":"Wei G, Twomey D, Lamb J, et al.: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331\u2013342.","journal-title":"Cancer Cell"},{"key":"24_CR57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1359-6349(08)72122-0","volume":"6","author":"P.J. Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Maris JM, et al.: Pediatric Preclinical Testing Program (PPTP) evaluation of rapamycin combined with cytotoxic drugs used frequently in treatment of childhood cancer [abstract 190]. Eur J Cancer Suppl 2008, 6:60.","journal-title":"Eur J Cancer Suppl"},{"key":"24_CR58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","volume":"278","author":"V. Lacronique","year":"1997","unstructured":"Lacronique V, Boureux A, Valle VD, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997:278:1309\u20131312.","journal-title":"Science"},{"key":"24_CR59","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","volume":"65","author":"A. Reiter","year":"2005","unstructured":"Reiter A, Walz C, Watmore A, et al.: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662\u20132667.","journal-title":"Cancer Res"},{"key":"24_CR60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20072182","volume":"205","author":"E. Flex","year":"2008","unstructured":"Flex E, Petrangeli V, Stella L, et al.: Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205:751\u2013758.","journal-title":"J Exp Med"},{"key":"24_CR61","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-07-4839","volume":"14","author":"E.G. Jeong","year":"2008","unstructured":"Jeong EG, Kim MS, Nam HK, et al.: Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008, 14:3716\u20133721.","journal-title":"Clin Cancer Res"},{"key":"24_CR62","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","volume":"372","author":"D. Bercovich","year":"2008","unstructured":"Bercovich D, Ganmore I, Scott LM, et al.: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome. Lancet 2008, 372:1484\u20131492.","journal-title":"Lancet"},{"key":"24_CR63","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","volume":"113","author":"L. Kearney","year":"2009","unstructured":"Kearney L, Gonzalez De Castro D, Yeung J, et al.: Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113:646\u2013648.","journal-title":"Blood"},{"key":"24_CR64","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","volume":"144","author":"A. Gaikwad","year":"2009","unstructured":"Gaikwad A, Rye CL, Devidas M, et al.: Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009, 144:930\u2013932.","journal-title":"Br J Haematol"},{"key":"24_CR65","unstructured":"Mullighan CG, Zhang J, Harvey RC, et al.: Frequent JAK mutations in pediatric acute lymphoblastic leukemia with poor outcome: A new therapeutic target in resistant disease [abstract LB-92]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO; April 18\u201322, 2009."},{"key":"24_CR66","doi-asserted-by":"crossref","unstructured":"Fridman J, Nussenzveig R, Liu P, et al.: Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract 3538]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3538.","DOI":"10.1182\/blood.V110.11.3538.3538"},{"key":"24_CR67","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kantarjian HM, Pardanani AD, et al.: The JAK inhibitor, INCB 018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia [abstract 1762]. Blood (ASH Annual Meeting Abstracts) 2008, 112: Abstract 1762.","DOI":"10.1182\/blood.V112.11.1762.1762"},{"key":"24_CR68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","volume":"13","author":"I. Geron","year":"2008","unstructured":"Geron I, Abrahamsson AE, Barroga CF, et al.: Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008, 13:321\u2013330.","journal-title":"Cancer Cell"},{"key":"24_CR69","doi-asserted-by":"crossref","unstructured":"Pardanani AD, Gotlib J, Jamieson CH, et al.: A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis [abstract 97]. Blood 2008, 112:Abstract 97.","DOI":"10.1182\/blood.V112.11.97.97"},{"key":"24_CR70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","volume":"3","author":"S.A. Armstrong","year":"2003","unstructured":"Armstrong SA, Kung AL, Mabon ME, et al.: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173\u2013183.","journal-title":"Cancer Cell"},{"key":"24_CR71","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","volume":"105","author":"P. Brown","year":"2005","unstructured":"Brown P, Levis M, Shurtleff S, et al.: FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005, 105:812\u2013820.","journal-title":"Blood"},{"key":"24_CR72","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"A.P. Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269\u2013271.","journal-title":"Science"},{"key":"24_CR73","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Stone RM, Silverman LB, et al.: A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias [abstract 6585]. J Clin Oncol 2006, 24 (18S):Abstract 6585.","DOI":"10.1200\/jco.2006.24.18_suppl.6585"},{"key":"24_CR74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","volume":"15","author":"P.J. Real","year":"2009","unstructured":"Real PJ, Tosello V, Palomero T, et al.: Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15:50\u201358.","journal-title":"Nat Med"},{"key":"24_CR75","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/13543784.15.12.1601","volume":"15","author":"F. Ravandi","year":"2006","unstructured":"Ravandi F, Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 2006, 15:1601\u20131613.","journal-title":"Expert Opin Investig Drugs"},{"key":"24_CR76","unstructured":"Houghton PJ, Maris JM, Courtright J, et al.: Initial testing of the histone deacetylase inhibitor vorinostat by the Pediatric Preclinical Testing Program [abstract C226]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA; October 22\u201326, 2007."},{"key":"24_CR77","unstructured":"Houghton PJ, Maris JM, Courtright J, et al.: Pediatric Preclinical Testing Program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib [abstract B118]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA; October 22\u201326, 2007."},{"key":"24_CR78","unstructured":"Smith MA, Morton CL, Maris JM, et al.: Pediatric Preclinical Testing Program (PPTP) evaluation of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) [abstract 2998]. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA; April 12\u201316, 2008."},{"key":"24_CR79","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21232","volume":"50","author":"J.M. Maris","year":"2008","unstructured":"Maris JM, Courtright J, Houghton PJ, et al.: Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008, 50:581\u2013587.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0024-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0024-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0024-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:58:00Z","timestamp":1589943480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0024-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,30]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0024-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,30]]}}}